vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Latham Group, Inc. (SWIM). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $100.0M, roughly 1.8× Latham Group, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -7.0%, a 20.4% gap on every dollar of revenue. On growth, Latham Group, Inc. posted the faster year-over-year revenue change (14.5% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $14.1M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -4.9%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Latham & Watkins LLP is an American multinational law firm. Founded in 1934 in Los Angeles, California, it is known for its litigation, corporate, and regulatory law practices.
AMPH vs SWIM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $100.0M |
| Net Profit | $24.4M | $-7.0M |
| Gross Margin | 46.8% | 28.0% |
| Operating Margin | 19.4% | -10.7% |
| Net Margin | 13.3% | -7.0% |
| Revenue YoY | -1.8% | 14.5% |
| Net Profit YoY | -35.7% | 76.0% |
| EPS (diluted) | $0.51 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $100.0M | ||
| Q3 25 | $191.8M | $161.9M | ||
| Q2 25 | $174.4M | $172.6M | ||
| Q1 25 | $170.5M | $111.4M | ||
| Q4 24 | $186.5M | $87.3M | ||
| Q3 24 | $191.2M | $150.5M | ||
| Q2 24 | $182.4M | $160.1M | ||
| Q1 24 | $171.8M | $110.6M |
| Q4 25 | $24.4M | $-7.0M | ||
| Q3 25 | $17.4M | $8.1M | ||
| Q2 25 | $31.0M | $16.0M | ||
| Q1 25 | $25.3M | $-6.0M | ||
| Q4 24 | $38.0M | $-29.2M | ||
| Q3 24 | $40.4M | $5.9M | ||
| Q2 24 | $37.9M | $13.3M | ||
| Q1 24 | $43.2M | $-7.9M |
| Q4 25 | 46.8% | 28.0% | ||
| Q3 25 | 51.4% | 35.4% | ||
| Q2 25 | 49.6% | 37.1% | ||
| Q1 25 | 50.0% | 29.5% | ||
| Q4 24 | 46.5% | 24.6% | ||
| Q3 24 | 53.3% | 32.4% | ||
| Q2 24 | 52.2% | 33.1% | ||
| Q1 24 | 52.4% | 27.7% |
| Q4 25 | 19.4% | -10.7% | ||
| Q3 25 | 13.2% | 13.3% | ||
| Q2 25 | 24.2% | 14.3% | ||
| Q1 25 | 21.9% | -4.4% | ||
| Q4 24 | 24.2% | -14.9% | ||
| Q3 24 | 29.8% | 8.9% | ||
| Q2 24 | 30.3% | 12.5% | ||
| Q1 24 | 27.9% | -1.9% |
| Q4 25 | 13.3% | -7.0% | ||
| Q3 25 | 9.0% | 5.0% | ||
| Q2 25 | 17.8% | 9.3% | ||
| Q1 25 | 14.8% | -5.4% | ||
| Q4 24 | 20.4% | -33.4% | ||
| Q3 24 | 21.1% | 3.9% | ||
| Q2 24 | 20.8% | 8.3% | ||
| Q1 24 | 25.1% | -7.1% |
| Q4 25 | $0.51 | $-0.06 | ||
| Q3 25 | $0.37 | $0.07 | ||
| Q2 25 | $0.64 | $0.13 | ||
| Q1 25 | $0.51 | $-0.05 | ||
| Q4 24 | $0.74 | $-0.24 | ||
| Q3 24 | $0.78 | $0.05 | ||
| Q2 24 | $0.73 | $0.11 | ||
| Q1 24 | $0.81 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | — |
| Total DebtLower is stronger | $608.7M | $279.8M |
| Stockholders' EquityBook value | $788.8M | $405.9M |
| Total Assets | $1.6B | $823.2M |
| Debt / EquityLower = less leverage | 0.77× | 0.69× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | — | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | — | ||
| Q1 24 | $289.6M | — |
| Q4 25 | $608.7M | $279.8M | ||
| Q3 25 | $608.6M | $281.1M | ||
| Q2 25 | $607.7M | $281.5M | ||
| Q1 25 | $603.9M | $306.9M | ||
| Q4 24 | $601.6M | $281.5M | ||
| Q3 24 | $596.4M | $282.8M | ||
| Q2 24 | $586.9M | $282.4M | ||
| Q1 24 | $594.0M | $282.8M |
| Q4 25 | $788.8M | $405.9M | ||
| Q3 25 | $776.7M | $408.4M | ||
| Q2 25 | $757.5M | $398.4M | ||
| Q1 25 | $751.3M | $381.1M | ||
| Q4 24 | $732.3M | $387.2M | ||
| Q3 24 | $727.7M | $416.6M | ||
| Q2 24 | $713.3M | $408.1M | ||
| Q1 24 | $672.4M | $391.8M |
| Q4 25 | $1.6B | $823.2M | ||
| Q3 25 | $1.7B | $844.4M | ||
| Q2 25 | $1.6B | $822.1M | ||
| Q1 25 | $1.6B | $824.6M | ||
| Q4 24 | $1.6B | $794.2M | ||
| Q3 24 | $1.5B | $853.4M | ||
| Q2 24 | $1.5B | $830.0M | ||
| Q1 24 | $1.6B | $808.6M |
| Q4 25 | 0.77× | 0.69× | ||
| Q3 25 | 0.78× | 0.69× | ||
| Q2 25 | 0.80× | 0.71× | ||
| Q1 25 | 0.80× | 0.81× | ||
| Q4 24 | 0.82× | 0.73× | ||
| Q3 24 | 0.82× | 0.68× | ||
| Q2 24 | 0.82× | 0.69× | ||
| Q1 24 | 0.88× | 0.72× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $23.3M |
| Free Cash FlowOCF − Capex | $24.6M | $14.1M |
| FCF MarginFCF / Revenue | 13.4% | 14.1% |
| Capex IntensityCapex / Revenue | 4.5% | 9.2% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $38.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $23.3M | ||
| Q3 25 | $52.6M | $51.0M | ||
| Q2 25 | $35.6M | $36.0M | ||
| Q1 25 | $35.1M | $-46.9M | ||
| Q4 24 | $29.0M | $6.2M | ||
| Q3 24 | $60.0M | $37.2M | ||
| Q2 24 | $69.1M | $52.4M | ||
| Q1 24 | $55.3M | $-34.5M |
| Q4 25 | $24.6M | $14.1M | ||
| Q3 25 | $47.2M | $45.2M | ||
| Q2 25 | $25.0M | $29.1M | ||
| Q1 25 | $24.4M | $-50.3M | ||
| Q4 24 | $16.6M | $-98.0K | ||
| Q3 24 | $46.2M | $33.2M | ||
| Q2 24 | $63.1M | $47.9M | ||
| Q1 24 | $46.5M | $-39.9M |
| Q4 25 | 13.4% | 14.1% | ||
| Q3 25 | 24.6% | 27.9% | ||
| Q2 25 | 14.3% | 16.8% | ||
| Q1 25 | 14.3% | -45.2% | ||
| Q4 24 | 8.9% | -0.1% | ||
| Q3 24 | 24.1% | 22.1% | ||
| Q2 24 | 34.6% | 29.9% | ||
| Q1 24 | 27.1% | -36.0% |
| Q4 25 | 4.5% | 9.2% | ||
| Q3 25 | 2.8% | 3.6% | ||
| Q2 25 | 6.1% | 4.0% | ||
| Q1 25 | 6.3% | 3.1% | ||
| Q4 24 | 6.7% | 7.2% | ||
| Q3 24 | 7.2% | 2.7% | ||
| Q2 24 | 3.3% | 2.8% | ||
| Q1 24 | 5.1% | 4.8% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 6.29× | ||
| Q2 25 | 1.15× | 2.25× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 6.32× | ||
| Q2 24 | 1.82× | 3.95× | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
SWIM
| In Ground Swimming Pools | $50.2M | 50% |
| Covers | $37.0M | 37% |
| Liners | $12.7M | 13% |
